Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953479 · ClinicalTrials.gov registry record · Phase 4
Implementing Low-Barrier HCV Treatment in a Jail Setting
A Phase 4 study of Implementation Science and Injection Drug Use, sponsored by Lifespan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06953479 is a Phase 4 study of Implementation Science and Injection Drug Use that is actively recruiting participants, run by Lifespan. The registered enrollment target is 40 participants, below the 1,741-participant average among 13 other Implementation Science trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06953479, a Phase 4 study of Implementation Science and Injection Drug Use, is actively recruiting participants, sponsored by Lifespan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial. The study asks: * Can a simplified, low-barrier HCV treatment program work in a jail setting? * Do participants finish treatment and get cured using this approach? All participants will receive a 12-week course of the HCV medication sofosbuvir/velpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work. Researchers will measure: * Whether participants are cured of HCV * Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity) * Whether the program could be used in other jails or expanded in the future This study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.
Conditions Studied
Interventions
- DRUG Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
- OTHER Community Health Worker
Study Locations (1)
Rhode Island
- Rhode Island Department of Corrections - Cranston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953479
The ClinicalTrials.gov registry entry for NCT06953479 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,741-participant average among 13 other Implementation Science trials with a reported enrollment target (98% lower). The listed sponsor is Lifespan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Implementation Science appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] is the first listed.
NCT06953479 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06953479 about?
NCT06953479 is a clinical study titled "Implementing Low-Barrier HCV Treatment in a Jail Setting". The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting t...
What is the current status of trial NCT06953479?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-06-11. Estimated completion is 2027-08.
What conditions does trial NCT06953479 study?
This clinical trial studies the following conditions: Implementation Science, Injection Drug Use, Hepatitis C (HCV), Incarceration.
What interventions are being tested in trial NCT06953479?
The interventions under investigation include: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] (DRUG), Community Health Worker (OTHER).
Who is sponsoring clinical trial NCT06953479?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06953479 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Implementation Science
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
RECRUITING · NA
-
K-ORCA: Testing a Decision Support Tool and Group Process for Selecting Interventions
RECRUITING · NA
-
Deimplementing CXR After CVC (DRAUP) in the ICU
RECRUITING · NA
-
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
RECRUITING · NA
-
Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers
RECRUITING · NA
-
Implementation Pilot of Preoperative CGA Before Major Surgery
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.